AnaptysBio completed the most consequential corporate event in its two-decade history just eleven trading days after its most recent quarter closed, distributing 100% of its biopharma pipeline into a newly public company called First Tracks Biotherapeutics, ticker TRAX, on April 20, 2026, and keeping for itself exactly two royalty streams: the Jemperli economics with GlaxoSmithKline and the imsidolimab economics with Vanda Pharmaceuticals. The Q1 FY2026 print filed May 12, 2026 for the period ended March 31, 2026 is therefore the last consolidated quarter in which the old Anaptys appears, with collaboration revenue of $25.6 million, a net loss of $52.9 million, and $286.5 million of cash and investments - and the business the market is now buying in ticker ANAB is a single-purpose royalty vehicle, not a development-stage biotech.
The single most important observation is that Jemperli, the anti-PD-1 antibody Anaptys licensed to GlaxoSmithKline back in 2014, generated roughly $313 million in first-quarter GSK sales, up more than 40% year over year on the partner's earnings call, and the royalties flowing to Anaptys rose 43% to $24.6 million in the same window, even as the company's reported collaboration revenue declined 8% year over year because a one-time $9.6 million Vanda license payment in the prior-year quarter did not repeat. The royalty trajectory and the headline revenue line moved in opposite directions during the quarter, and reading the result as a top-line miss would miss the underlying business entirely.
The mechanism, in our view, is that Sagard Healthcare Royalty Partners holds a non-recourse claim against the Jemperli royalty stream totaling $240.8 million as of March 31, 2026, with the agreement sized to terminate once cumulative receipts reach either $600 million by March 31, 2031 or $675 million thereafter. Anaptys projects Sagard reaches roughly $275 million of cumulative receipts by Q1 2026 and estimates the remaining $325 million of monetization liability pays off by the end of Q2 2027, after which 100% of every Jemperli dollar flows to the Anaptys balance sheet. The market is therefore being asked to value a near-term, single-asset royalty stream against a backdrop of $52.9 million of quarterly net losses, $14.2 million of non-cash stock compensation, and a court trial in Delaware Chancery Court scheduled to begin July 14, 2026 in which Anaptys is asking the court to declare its 2014 collaboration agreement with GlaxoSmithKline still in force.
The load-bearing risk is the GlaxoSmithKline litigation. On April 24, 2026, a Delaware court dismissed Tesaro's counterclaim that Anaptys had materially breached the agreement, but the remaining claims proceed to trial in July; an adverse ruling could call into question the company's right to collect ongoing royalties on the second most important oncology asset in GlaxoSmithKline's portfolio. The market is also watching for the second key milestone of the year: the Phase 2 AZUR-1 readout of dostarlimab monotherapy in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer, expected in the second half of 2026, which carries an FDA Breakthrough Therapy Designation and a Commissioner's National Priority Voucher that compresses the Biologics License Application review to one to two months. A clean AZUR-1 readout would expand the eligible patient population, accelerate Sagard paydown, and bring the $390 million annualized royalty target management has guided to as early as 2029 into closer reach.